Literature DB >> 20948306

Reactivation of MASPIN in non-small cell lung carcinoma (NSCLC) cells by artificial transcription factors (ATFs).

Adriana S Beltran1, Pilar Blancafort.   

Abstract

Tumor suppressor genes have antiproliferative and antimetastatic functions, and thus, they negatively affect tumor progression. Reactivating specific tumor suppressor genes would offer an important therapeutic strategy to block tumor progression. Mammary Serine Protease Inhibitor (MASPIN) is a tumor suppressor gene that is not mutated or rearranged in tumor cells, but is silenced during metastatic progression by transcriptional and epigenetic mechanisms. In this work, we have investigated the ability of Artificial Transcription Factors (ATFs) to reactivate MASPIN expression and to reduce tumor growth and metastatic dissemination in Non-Small Cell Lung Carcinoma (NSCLC) cell lines carrying a hypermethylated MASPIN promoter. We found that the ATFs linked to transactivator domains were able to demethylate the MASPIN promoter. Consistently, we observed that co-treatment of ATF-transduced cells with methyltransferase inhibitors enhanced MASPIN expression as well as induction of tumor cell apoptosis. In addition to tumor suppressive functions, restoration of endogenous MASPIN expression was accompanied by inhibition of metastatic dissemination in nude mice. ATF-mediated reactivation of MASPIN lead to changes in cell motility and to induction of E-CADHERIN. These data suggest that ATFs are able to reprogram aggressive lung tumor cells towards a more epithelial, differentiated phenotype, and thus, represent novel therapeutic agents for metastatic lung cancers.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20948306      PMCID: PMC3278788          DOI: 10.4161/epi.6.2.13700

Source DB:  PubMed          Journal:  Epigenetics        ISSN: 1559-2294            Impact factor:   4.528


  62 in total

1.  5-Aza-2'-deoxycytidine-mediated reductions in G9A histone methyltransferase and histone H3 K9 di-methylation levels are linked to tumor suppressor gene reactivation.

Authors:  R J Wozniak; W T Klimecki; S S Lau; Y Feinstein; B W Futscher
Journal:  Oncogene       Date:  2006-06-26       Impact factor: 9.867

2.  Targeted expression of maspin in tumor vasculatures induces endothelial cell apoptosis.

Authors:  Zhigang Li; Heidi Y Shi; Ming Zhang
Journal:  Oncogene       Date:  2005-03-17       Impact factor: 9.867

3.  Decreased immunoreactive maspin expression in intermediate thickness and thick primary melanoma lesions.

Authors:  P Vereecken; S Reynaert; M C Lalmand; K Zouaoui-Boudjeltia; M Heenen; B Van Den Heule; M Petein
Journal:  J Int Med Res       Date:  2006 Jan-Feb       Impact factor: 1.671

Review 4.  Maspin. A tumor suppressing serpin.

Authors:  R Sager; S Sheng; P Pemberton; M J Hendrix
Journal:  Adv Exp Med Biol       Date:  1997       Impact factor: 2.622

5.  Prognostic significance of the tumor suppressor gene maspin in non-small cell lung cancer.

Authors:  Kyoji Hirai; Kiyoshi Koizumi; Shuji Haraguchi; Tomomi Hirata; Iwao Mikami; Mitsuhiro Fukushima; Shigeki Yamagishi; Tetsuo Kawashima; Daisuke Okada; Kazuo Shimizu; Masashi Kawamoto
Journal:  Ann Thorac Surg       Date:  2005-01       Impact factor: 4.330

6.  Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells.

Authors:  Z Zou; A Anisowicz; M J Hendrix; A Thor; M Neveu; S Sheng; K Rafidi; E Seftor; R Sager
Journal:  Science       Date:  1994-01-28       Impact factor: 47.728

7.  MicroRNA-21 targets tumor suppressor genes in invasion and metastasis.

Authors:  Shuomin Zhu; Hailong Wu; Fangting Wu; Daotai Nie; Shijie Sheng; Yin-Yuan Mo
Journal:  Cell Res       Date:  2008-03       Impact factor: 25.617

8.  Maspin expression inhibits osteolysis, tumor growth, and angiogenesis in a model of prostate cancer bone metastasis.

Authors:  Michael L Cher; Hector R Biliran; Sunita Bhagat; Yonghong Meng; Mingxin Che; Jaron Lockett; Judith Abrams; Rafael Fridman; Michael Zachareas; Shijie Sheng
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-03       Impact factor: 11.205

9.  Regulating the tumor suppressor gene maspin in breast cancer cells: a potential mechanism for the anticancer properties of tamoxifen.

Authors:  Zhila Khalkhali-Ellis; Abby L Christian; Dawn A Kirschmann; Elijah M Edwards; Maryam Rezaie-Thompson; Mohammad A Vasef; Lynn M Gruman; Richard E B Seftor; Laura E Norwood; Mary J C Hendrix
Journal:  Clin Cancer Res       Date:  2004-01-15       Impact factor: 12.531

10.  IRF6 in development and disease: a mediator of quiescence and differentiation.

Authors:  Caleb M Bailey; Mary J C Hendrix
Journal:  Cell Cycle       Date:  2008-04-29       Impact factor: 4.534

View more
  24 in total

1.  Re-expression of Selected Epigenetically Silenced Candidate Tumor Suppressor Genes in Cervical Cancer by TET2-directed Demethylation.

Authors:  Christian Huisman; Monique G P van der Wijst; Matthijs Schokker; Pilar Blancafort; Martijn M Terpstra; Klaas Kok; Ate G J van der Zee; Ed Schuuring; G Bea A Wisman; Marianne G Rots
Journal:  Mol Ther       Date:  2015-12-21       Impact factor: 11.454

2.  Prolonged re-expression of the hypermethylated gene EPB41L3 using artificial transcription factors and epigenetic drugs.

Authors:  Christian Huisman; Monique G P van der Wijst; Fahimeh Falahi; Juul Overkamp; Gellért Karsten; Martijn M Terpstra; Klaas Kok; Ate G J van der Zee; Ed Schuuring; G Bea A Wisman; Marianne G Rots
Journal:  Epigenetics       Date:  2015-04-01       Impact factor: 4.528

Review 3.  Writing and rewriting the epigenetic code of cancer cells: from engineered proteins to small molecules.

Authors:  Pilar Blancafort; Jian Jin; Stephen Frye
Journal:  Mol Pharmacol       Date:  2012-11-13       Impact factor: 4.436

4.  The p16-specific reactivation and inhibition of cell migration through demethylation of CpG islands by engineered transcription factors.

Authors:  Baozhen Zhang; Shengyan Xiang; Qiming Zhong; Yanru Yin; Liankun Gu; Dajun Deng
Journal:  Hum Gene Ther       Date:  2012-08-27       Impact factor: 5.695

5.  Epigenetic reprogramming of cancer cells via targeted DNA methylation.

Authors:  Ashley G Rivenbark; Sabine Stolzenburg; Adriana S Beltran; Xinni Yuan; Marianne G Rots; Brian D Strahl; Pilar Blancafort
Journal:  Epigenetics       Date:  2012-04-01       Impact factor: 4.528

6.  Targeting serous epithelial ovarian cancer with designer zinc finger transcription factors.

Authors:  Haydee Lara; Yuhua Wang; Adriana S Beltran; Karla Juárez-Moreno; Xinni Yuan; Sumie Kato; Andrea V Leisewitz; Mauricio Cuello Fredes; Alexei F Licea; Denise C Connolly; Leaf Huang; Pilar Blancafort
Journal:  J Biol Chem       Date:  2012-07-10       Impact factor: 5.157

7.  Functional validation of putative tumor suppressor gene C13ORF18 in cervical cancer by Artificial Transcription Factors.

Authors:  Christian Huisman; G Bea A Wisman; Hinke G Kazemier; Marcel A T M van Vugt; Ate G J van der Zee; Ed Schuuring; Marianne G Rots
Journal:  Mol Oncol       Date:  2013-03-05       Impact factor: 6.603

8.  Breaking through an epigenetic wall: re-activation of Oct4 by KRAB-containing designer zinc finger transcription factors.

Authors:  Karla Juárez-Moreno; Rafaela Erices; Adriana S Beltran; Sabine Stolzenburg; Mauricio Cuello-Fredes; Gareth I Owen; Haili Qian; Pilar Blancafort
Journal:  Epigenetics       Date:  2013-01-11       Impact factor: 4.528

9.  Epigenetic editing of the Dlg4/PSD95 gene improves cognition in aged and Alzheimer's disease mice.

Authors:  Fernando J Bustos; Estibaliz Ampuero; Nur Jury; Rodrigo Aguilar; Fahimeh Falahi; Jorge Toledo; Juan Ahumada; Jaclyn Lata; Paula Cubillos; Berta Henríquez; Miguel V Guerra; Jimmy Stehberg; Rachael L Neve; Nibaldo C Inestrosa; Ursula Wyneken; Marco Fuenzalida; Steffen Härtel; Miguel Sena-Esteves; Lorena Varela-Nallar; Marianne G Rots; Martin Montecino; Brigitte van Zundert
Journal:  Brain       Date:  2017-12-01       Impact factor: 13.501

10.  Bidirectional modulation of endogenous EpCAM expression to unravel its function in ovarian cancer.

Authors:  B T F van der Gun; C Huisman; S Stolzenburg; H G Kazemier; M H J Ruiters; P Blancafort; M G Rots
Journal:  Br J Cancer       Date:  2013-02-12       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.